Tofacitinib is a JAK1/2/3 inhibitor approved for RA that primarily inhibits JAK1 and JAK 3 and, to a lesser extent, JAK2 and TYK 2.273. The gene discussed is JAK1; the disease is rheumatoid arthritis.